Massive Bio

Massive Bio’s mission is to provide access to clinical trials for every cancer patient regardless of his/her location and/or financial stability. Massive Bio is an AI-driven platform connecting cancer patients and their oncologists to bio-pharmaceutical clinical trials, yielding a profound improvement in access and match rates, leading to faster drug development timelines, and creating a novel oncology data ecosystem for improved protocol design and real-world insights.

Massive Bio controls the patient enrollment value chain starting with patient identification, following with AI-based virtual pre-screening outside the site, and resolving last mile issues for clinical trial enrollment. While improving cancer patients' lives, Massive Bio serves close to two dozen pharmaceutical companies, contract research organizations (CROs), and hospital networks.

In addition, Massive Bio has been awarded an SBIR contract by the National Cancer Institute (NCI) to develop and characterize it's Deep Learning Clinical Trial Matching System (DLCTMS), Contract No. 75N91020C00016. Massive Bio provides oncology dedicated patient recruitment, site selection, real-world data services, and AI-based trial pre-screening services to its enterprise customers. Massive Bio was founded in 2015, is headquartered in NYC, and is privately funded by strategic and financial investors.